'Final' Pfizer bid to acquire AstraZeneca rejected; La Jolla research jobs remain unaffected
Published - 05/20/14 - 01:19 PM | 2234 views | 0 0 comments | 3 3 recommendations | email to a friend | print
In a failed attempt to reach a deal that would have restored its status as the world’s largest pharmaceutical company, biotechnology giant Pfizer Inc. – whose five-facility La Jolla site specializes in the manufacture of cancer drugs – has been turned down in what it terms its final offer to acquire AstraZeneca.

On Sunday, May 18, the British pharmaceutical giant rejected Pfizer’s $119 billion offer, potentially saving research posts at the La Jolla facility.

“Pfizer has a history of shutting down facilities,” said Raghuran Selvaraju, an analyst with Aegis Capital. “They don't thin down head count; they shut down an entire facility and pick up their stakes and move away.”

AstraZeneca recently rejected Pfizer’s previous cash and stock offer of $106 billion.

Pfizer's 25-acre La Jolla campus, on Science Center Drive near the I-5 and Sorrento Valley Highway intersection, includes five buildings totaling more than 500,000 square feet. The company spent $5.7 billion on research and development in 2013, down from $7.48 billion in 2012.

Pfizer would not disclose how many people work at the La Jolla facilities or other U.S. research centers.

Comments-icon Post a Comment
No Comments Yet
Comments are back! Simply post the comment (it'll complain about you failing the human test) then simply click on the captcha and then click "Post Comment" again. Comments are also welcome on our Facebook page.